undamentalytics Newsletter
Sign in

Kura Oncology, Inc. revenue

Kura Oncology, Inc.'s revenue was $67.5m in fiscal 2025, up 25.2% on the year before. Over the last twelve months it was $77.2m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0546777
Growth on the year before——+25.2%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
License and Collaboration Revenue $65.3M ▲ 21.3%
Collaboration Revenue $65.3M ▲ 21.3%
Products $2.1M —

These categories overlap or exclude eliminations, so shares aren't shown.

From Kura Oncology, Inc.'s 10-K filed March 5, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Kura Oncology, Inc. $77.2m — —
ADC Therapeutics SA $79.6m 3.0% —
Assembly Biosciences, Inc. $74.8m 125.1% -3.3%
Ascentage Pharma Group International $79.9m -41.4% —
Protalix Biotherapeutics, Inc. $80.6m 30.1% 6.1%
Compugen LTD $72.8m 161.1% 302.6%

Compare with peers

Head to head: ADCT vs KURAASMB vs KURAAAPG vs KURA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kura Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kura Oncology, Inc.